Abstract:334 Background: Prostate cancer (PCa) screening has relied on prostate-specific antigen (PSA) levels to screen patients for biopsy. However, the limited specificity of serum PSA leads to high rates of negative biopsies and detection of clinically insignificant cancers. Tumor-derived extracellular vesicles, microscopic particles released by tumor cells and ubiquitously found in all bodily fluids, have emerged as novel biomarkers for a diverse set of malignancies. This study explored the utility of urine prostate-specific extracellular vesicles (ProsEVs) identified by unique surface protein markers with novel flow cytometry-based techniques as biomarkers for PCa screening. Methods: This prospective study recruited at a tertiary care center between Oct 2019 and Mar 2022. Patients with PSA≥2 ng/ml underwent prebiopsy mpMRI followed by transperineal prostate biopsy (PI-RADS 1-2) or combined MRI-guided biopsy (PI-RADS ≥ 3). Patients with metastatic PCa or prior systemic therapy were excluded. Urine samples were collected at MRI using Colli-Pee. ProsEVs were labeled using monoclonal antibodies for PSMA and STEAP1 and ProsEV concentrations were determined using nanoscale flow cytometry. EV densities were calculated by normalizing EV counts to prostate volume. Multivariable logistic regression models were constructed and model performance was compared used ROC curve analysis. Results: This study had a total of 179 patients prospectively recruited, 95 were diagnosed with Gleason score (GS) ≥ 7 prostate cancer (csPCa), while the remaining had GS <7 or benign disease. Analysis of urinary ProsEV densities revealed a significant dose-response relationship between benign, GS <7 PCa and GS ≥ 7 PCa groups and ProsEV densities (p=0.01 for PSMA, and <0.001 for STEAP1). The log sum of the PSMA and STEAP1 EV densities exhibited the strongest correlation with other ProsEV variables and was selected for model development. ROC curve analysis showed that the final model including Log Sum ProsEVs, PSA, and PI-RADS outperformed one including PSA and PI-RADS (0.733 vs 0.651, p=0.02). Specificity for detecting csPCa at a sensitivity of 90% was 39.5% in the final model compared to 37% for PSA and PI-RADS (Table). Conclusions: This study highlights the potential of urine ProsEVs as novel biomarkers for improving screening specificity for csPCa detection. Future works should explore analysis of intra-ProsEV content to further improve specificity and advance liquid biopsy techniques. [Table: see text]

Extracellular vesicles such as prostate cancer cell fragments as a fluid biopsy for prostate cancer

Extracellular vesicles: the next generation of biomarkers for liquid biopsy-based prostate cancer diagnosis

Small extracellular vesicles: Roles and clinical application in prostate cancer

Liquid biopsy of extracellular vesicle biomarkers for prostate cancer personalized treatment decision

Tumor-derived extracellular vesicle nucleic acids as promising diagnostic biomarkers for prostate cancer

Abstract B047: Characterizing the landscape of extracellular vesicles from prostate cancer cell lines

Application of extracellular vesicles in the diagnosis and treatment of prostate cancer: Implications for clinical practice

Extracellular vesicles as a source of prostate cancer biomarkers in liquid biopsies: a decade of research

Extracellular Vesicles in Liquid Biopsies as Biomarkers for Solid Tumors

Exploring the utility of prostate-derived extracellular vesicles as a urine biomarker for clinically significant prostate cancer.

Extracellular Vesicles: Recent Developments in Technology and Perspectives for Cancer Liquid Biopsy

Prostate cancer-derived extracellular vesicles metabolic biomarkers: Emerging roles for diagnosis and prognosis

Plasma and urinary extracellular vesicles as a source of RNA biomarkers for prostate cancer in liquid biopsies

Extracellular vesicles and prostate cancer management: a narrative review

Single Extracellular Vesicle Analysis Using Droplet Microfluidics.

Optimising Extracellular Vesicle Metabolomic Methodology for Prostate Cancer Biomarker Discovery

The biological function of extracellular vesicles in prostate cancer and their clinical application as diagnostic and prognostic biomarkers

Proteomic Identification of Small Extracellular Vesicle Proteins LAMB1 and Histone H4 for Prostate Cancer Diagnosis and Risk Stratification

Diagnosis of Prostate Cancer Metastasis via Extracellular Vesicles Isolated Using Two‐Phase Interface as Membrane‐Less Filter

Extracellular Vesicles as Liquid Biopsy Biomarkers across the Cancer Journey: From Early Detection to Recurrence

Exosomes as A Next-Generation Diagnostic and Therapeutic Tool in Prostate Cancer